Cellectis S.A. (FRA:ZVAA)

Germany flag Germany · Delayed Price · Currency is EUR
4.040
-0.020 (-0.49%)
At close: Dec 4, 2025
113.76%
Market Cap 297.98M
Revenue (ttm) 70.36M
Net Income (ttm) -30.13M
Shares Out n/a
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 637
Open 4.040
Previous Close 4.060
Day's Range 4.040 - 4.040
52-Week Range 0.950 - 4.580
Beta n/a
RSI 58.86
Earnings Date Mar 10, 2026

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, a gene-edited allogeneic CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric an... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 222
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol ZVAA
Full Company Profile

Financial Performance

In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.